Table 1.
Patient demographics at diagnosis
| Variables | All patients (n-1595) |
Patients with eGFR ≥60 ml/min (n-843) |
Patients with eGFR 30–59 ml/min (n-595) |
Patients with eGFR < 30 ml/min (n-157) |
P value |
|---|---|---|---|---|---|
| Median eGFR at diagnosis (ml/min/1.73 m2) (IQR) | 61 (45–79) | 78 (68–92) | 48 (40–54) | 21 (16–25) | < 0.001 |
| Treatment arm | |||||
| Intensive (%) | 907 (56.9) | 536 (63.6) | 290 (48.7) | 81 (51.6) | < 0.001 |
| Non-intensive (%) | 688 (43.1) | 307 (36.4) | 305 (51.3) | 76 (48.4) | |
| Median age - years (IQR) | 66 (58–73) | 64 (57–70) | 67 (60–75) | 67 (60–73) | < 0.001 |
| Gender | |||||
| Male (%) | 959 (60.1) | 531 (62.9) | 342 (57.4) | 86 (54.7) | 0.04 |
| Female (%) | 631 (39.5) | 311 (36.9) | 250 (42.0) | 70 (44.6) | |
| Unknown (%) | 5 (0.3) | 1 (0.1) | 3 (0.5) | 1 (0.6) | |
| Myeloma Type | |||||
| IgG (%) | 977 (61.2) | 534 (63.3) | 371 (62.3) | 72 (45.8) | < 0.001 |
| IgA (%) | 347 (21.7) | 194 (23.0) | 130 (21.8) | 23 (14.6) | |
| IgM (%) | 9 (0.5) | 8 (0.9) | – | 1 (0.6) | |
| IgD (%) | 30 (1.9) | 13 (1.5) | 12 (2.0) | 5 (3.2) | |
| LCO (%) | 215 (13.5) | 83 (9.8) | 76 (12.8) | 56 (35.7) | |
| Non-secretory myeloma (%) | 17 (1.1) | 11 (1.3) | 6 (1.0) | – | |
| FLC type | |||||
| Kappa (%) | 1029 (65.2) | 568 (68.3) | 373 (63.3) | 88 (56.1) | 0.006 |
| Lambda (%) | 549 (34.8) | 264 (31.7) | 216 (36.7) | 69 (43.9) | |
| Involved FLC level (mg/L) | |||||
| Median Kappa FLC (IQR) | 391.20 (79.51–1106.00) |
224.10 (36.96–632.20) |
474.60 (115.20–1427.00) |
2217.00 (668.30–5424.00) |
< 0.001 |
| Median Lambda FLC (IQR) | 503.00 (90.65–1848.00) |
266.90 (57.11–942.10) |
722.50 (151.40–2022.00) |
3071.00 (1181.00–9079.00) |
|